European Commission logo
English English
CORDIS - EU research results

Nano-assisted digitalizing of cancer phenotyping for immunotherapy

Project description

Informed decision on immunotherapy

Immunotherapy constitutes a very promising strategy that activates a person’s own immune system to fight cancer and creates anti-cancer immunity. However, clinical practice has shown that immunotherapy can lead to autoimmune reactions, indicating that careful planning is required. Funded by the European Research Council, the ImmunoChip project aims to develop a platform that will be able to predict a person’s suitability to receive immunotherapy. The ImmunoChip device will combine microfluidics and a nanosensory network to study various aspects of the individual cancer and its microenvironment. Alongside information on immune system components, the platform will help clinicians make an informed decision on the type of immunotherapy for a patient.


Every day cancer takes about 30000 lives worldwide, despite multiple treatments developed in the last 50 years. True revolution in the therapy is demonstrated by the immunooncology relying on multiple routes to activate the immune system, using e.g. Chimeric Antigen Receptors, checkpoints inhibitors. Although demonstrating success in the treatment of e.g. lymphoma, the percentage of patients responding to the immunotherapy is less than 30%. Even more, the activation of immune system does not happen at no cost, leading to severe auto-immune reactions, sometimes with lethal consequences. Therefore, the main question of clinicians is: how to efficiently predict the response/no-response of the patient to the immunotherapy? At present, there is no predictive technological platform combining both, highly sensitive analysis of the cancer immunity and the planning of the strategy for potential therapy.
I consider cancer as a smart self-adapting machine that plays its own set of rules: it generates and quenches the biochemical signals; initiates the iterative loops and builds up feedback controls to create an immune suppressive environment. My idea is to digitalize these mechanisms. ‘ImmunoChip’ will develop a device combining microfluidics with the specific nanosensory network to study elements of the cancer-immunity cycle to bring a new dimension in the field of preclinical immunotherapeutic cancer phenotyping. The information about the immunosuppressive activity of the cancer microenvironment, immune checkpoints, T cells, efficiency of the immunotherapy, will be collected into respective data patterns. The developed ‘ImmunoChip’ platform will help to answer the questions: can the patient be treated with the immunotherapy? How does the tumor protect itself? Which immunotherapy to use? I am sure that improved decision-making in immunotherapy will lead to a transformative treatment results for more patients and will help to save more lives.

Host institution

Net EU contribution
€ 1 993 875,00
01328 Dresden

See on map

Sachsen Dresden Dresden, Kreisfreie Stadt
Activity type
Research Organisations
Total cost
€ 1 993 875,00

Beneficiaries (1)